You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 7, 2025

Drug Price Trends for PACERONE


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for PACERONE

Average Pharmacy Cost for PACERONE

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug NameNDCPrice/Unit ($)UnitDate
PACERONE 400 MG TABLET 00245-1645-89 0.74189 EACH 2025-03-19
PACERONE 100 MG TABLET 00245-0144-01 0.76993 EACH 2025-03-19
PACERONE 100 MG TABLET 00245-0144-89 0.76993 EACH 2025-03-19
>Drug Name>NDC>Price/Unit ($)>Unit>Date
Showing 1 to 3 of 3 entries

Market Analysis and Price Projections for Pacerone (Amiodarone Hydrochloride)

Introduction to Pacerone

Pacerone, known generically as amiodarone hydrochloride, is a member of the group III antiarrhythmics drug class. It is primarily used for the treatment of life-threatening arrhythmias, including ventricular fibrillation and hemodynamically unstable tachycardia, in patients who have not responded to other available antiarrhythmics or cannot tolerate alternative agents[4].

Market Trends and Drivers

Increasing Geriatric Population

The global amiodarone hydrochloride market is driven by an increase in the geriatric population, which is at a higher risk of sudden deaths due to life-threatening ventricular arrhythmias. This demographic shift is expected to boost the demand for amiodarone hydrochloride[1].

Rise in Sedentary Lifestyle

The sedentary lifestyle of many individuals has led to an increase in heart-related problems and other chronic disorders, further driving the growth of the amiodarone hydrochloride market[1].

Impact of COVID-19

The COVID-19 pandemic has significantly impacted the pharmaceutical and biotechnology industries, including the market for amiodarone hydrochloride. The high demand for COVID-19 management drugs has presented opportunities for manufacturers, although it also poses challenges such as supply chain disruptions and increased competition[1].

Market Size and Growth Projections

The global amiodarone market is expected to experience significant growth from 2024 to 2031. The market size is projected to increase due to the rising incidence of arrhythmias and the expanding geriatric population. According to market reports, the compound annual growth rate (CAGR) for the amiodarone market is expected to be substantial during this period[3].

Key Players and Competitive Landscape

The amiodarone hydrochloride market is competitive, with several key players such as Sanofi, Piramal Pharma Limited, Shanghai Pharmaceutical Group Co., Unichem Laboratories Limited, and others. These companies are focusing on strategies to strengthen their product portfolios and expand their market presence. For instance, in 2018, Mayne Pharma Group Limited launched a generic version of amiodarone 200mg tablets in the U.S., and in 2021, Piramal Pharma Limited acquired Hemmo Pharmaceuticals Pvt Ltd. to enhance its product portfolio[1][3].

Price Analysis

Current Pricing

The prices of Pacerone (amiodarone hydrochloride) vary based on the dosage and quantity. Here are some current price ranges:

  • 100 mg Oral Tablet: Around $67.67 for 30 tablets[5].
  • 200 mg Oral Tablet: Around $35.83 for 30 tablets, and $62.17 for 60 tablets[2][5].
  • 400 mg Oral Tablet: Around $403.37 for 30 tablets[2].

Price Projections

Given the increasing demand and the competitive landscape, prices are expected to remain relatively stable or see a slight increase. However, generic versions of the drug, which are already available, may help in keeping the prices competitive. The use of discount cards and patient assistance programs can also reduce the cost for consumers[2][5].

Distribution Channels and Accessibility

Amiodarone hydrochloride is available through various distribution channels, including pharmacies and online platforms. The drug is widely accepted by major pharmacy chains, and discount cards like the Drugs.com Discount Card can help reduce the cost for cash-paying customers[2][5].

Side Effects and Safety Concerns

Despite its efficacy, Pacerone is associated with significant toxicity, including pulmonary, hepatic, and cardiac toxicity. These side effects can be severe and sometimes fatal. For instance, pulmonary toxicity has been reported in up to 17% of patients, with a fatality rate of about 10%[4].

Regulatory and Safety Guidelines

Due to the substantial toxicity associated with amiodarone hydrochloride, its use is strictly regulated. Patients must undergo regular monitoring, including baseline chest X-rays, pulmonary function tests, and liver transaminase tests. The drug should be initiated in a clinical setting where continuous electrocardiograms and cardiac resuscitation are available[4].

Market Opportunities and Challenges

Opportunities

  • The growing demand for antiarrhythmic drugs due to an increase in cardiovascular diseases.
  • Expansion into emerging markets where access to such medications is limited.
  • Development of generic versions to increase market competition and reduce prices[1][3].

Challenges

  • Significant side effects and toxicity associated with the drug.
  • Regulatory hurdles and strict monitoring requirements.
  • Competition from other antiarrhythmic drugs and potential new entrants in the market[1][4].

Regional Analysis

The amiodarone hydrochloride market is analyzed at the global, regional, and country levels. Developed countries face a higher demand due to the prevalence of heart-related disorders, while emerging markets offer growth opportunities due to increasing healthcare access and awareness[3].

Key Takeaways

  • The amiodarone hydrochloride market is driven by an increasing geriatric population and a rise in sedentary lifestyles.
  • The market is expected to grow significantly from 2024 to 2031 due to rising demand and expanding product portfolios of key players.
  • Prices are expected to remain competitive, with generic versions and discount programs available.
  • Significant toxicity and safety concerns necessitate strict regulatory guidelines and patient monitoring.
  • Market opportunities include expansion into emerging markets and the development of generic versions.

FAQs

What is Pacerone used for?

Pacerone (amiodarone hydrochloride) is used for the treatment of life-threatening arrhythmias, including ventricular fibrillation and hemodynamically unstable tachycardia, in patients who have not responded to other available antiarrhythmics or cannot tolerate alternative agents[4].

What are the common side effects of Pacerone?

Common side effects include pulmonary toxicity, hepatic toxicity, and cardiac toxicity. These can be severe and sometimes fatal[4].

How much does Pacerone cost?

The cost of Pacerone varies based on dosage and quantity. For example, a 200 mg oral tablet can cost around $35.83 for 30 tablets[2][5].

Are there generic versions of Pacerone available?

Yes, generic versions of amiodarone hydrochloride are available, which can help in reducing the cost for consumers[2][5].

What are the regulatory guidelines for using Pacerone?

Due to its significant toxicity, Pacerone should be initiated in a clinical setting with continuous electrocardiograms and cardiac resuscitation available. Regular monitoring, including baseline chest X-rays and liver transaminase tests, is required[4].

Sources

  1. Allied Market Research: Amiodarone Hydrochloride Market Size | Segment Growth- 2030
  2. Drugs.com: Pacerone Prices, Coupons, Copay Cards & Patient Assistance
  3. Cognitive Market Research: Amiodarone Market Report 2024 (Global Edition)
  4. DailyMed: Pacerone - amiodarone hydrochloride tablet
  5. Drugs.com: Amiodarone Prices, Coupons, Copay Cards & Patient Assistance

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.